A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

Recruiting now · Phase 2

Conditions studied: Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure, Focal Seizure, Focal Onset Seizure

In brief

This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.

Key facts

Study ID
NCT07219407
Run by
Rapport Therapeutics Inc.
People needed
30
Starts
2025-12-15
Expected to finish
2028-02-03
Last updated by the study team
2026-01-23

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.